Roth Keeps Pharmacyclics (PCYC) at Buy; Still Positive on Imbruvica Following Phase III RESONTAE
Tweet Send to a Friend
Roth Capital maintains Pharmacyclics (Nasdaq: PCYC) at Buy with a target price of $183 following recent presentations at ASCO.Analyst Joseph ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
